Do you want to read an article? Please log in or register.
Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine
Migraine and Headache
Related content
RECOMMENDED
Migraine and Headache
Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double-Blind, Placebo-Controlled REGAIN, and Pooled EVOLVE-1 and EVOLVE-2 Studies
★ 1
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
Headache
Smitherman TA, Tietjen GE, Schuh K, Skljarevski V, Lipsius S, D'Souza DN, Pearlman EM
doi: 10.1111/head.13970
RECOMMENDED
Migraine and Headache
Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study
doi: 10.1177/0333102419835459.
RECOMMENDED
Migraine and Headache
Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study
Neurology.
Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK
doi: 10.1212/WNL.
RECOMMENDED
Migraine and Headache
Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment
★ 3
Recommended by
Prof. Dr Christian Kamm, Faculty Member
★ 1
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
Cephalalgia.
Dodick DW, Goadsby PJ, Lucas C, Jensen R, Bardos JN, Martinez JM, Zhou C, Aurora SK, Yang JY, Conley RR, Oakes T
doi: 10.1177/0333102420905321.
Migraine and Headache
Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial
Lancet Neurol.
Mulleners WM, Kim BK, Láinez MJA, Lanteri-Minet M, Pozo-Rosich P, Wang S, Tockhorn-Heidenreich A, Aurora SK, Nichols RM, Yunes-Medina L, Detke HC
doi: 10.1016/S1474-4422(20)30279-9.
Migraine and Headache
Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies
Headache.
Detke HC, Millen BA, Zhang Q, Samaan K, Ailani J, Dodick DW, Aurora SK
doi: 10.1111/head.13691.
Migraine and Headache
Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headache
Headache
Marmura MJ, Diener HC, Cowan RP, Tepper SJ, Diamond ML, Starling AJ, Hirman J, Mehta L, Brevig T, Cady R
doi: 10.1111/head.14206
Migraine and Headache
Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b FOCUS study
Headache
Spierings ELH, Ning X, Ramirez Campos V, Cohen JM, Barash S, Buse DC
doi: 10.1111/head.14196
RECOMMENDED
Migraine and Headache
Acute withdrawal and botulinum toxin A in chronic migraine with medication overuse: a double-blind randomized controlled trial
Brain.
Pijpers JA, Kies DA, Louter MA, van Zwet EW, Ferrari MD, Terwindt GM
doi: 10.1093/